Wedbush Maintains Neutral on Cogent Biosciences, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten maintains a Neutral rating on Cogent Biosciences (COGT) and raises the price target from $5 to $10.
February 23, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten maintains a Neutral rating on Cogent Biosciences and raises the price target from $5 to $10.
The increase in price target from $5 to $10 by a reputable analyst suggests a positive outlook on the company's valuation, potentially leading to increased investor interest and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100